Vertex Pharmaceuticals raises full-year revenue guidance following Q3 results
1 report, 1 independent
Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Vertex Pharmaceuticals reported 12% year-over-year revenue growth in the third quarter of 2026, supported by its cystic fibrosis franchise and newer products. The company also raised its full-year revenue guidance to a range of $13.15 billion to $13.25 billion.
From dailypolitical.com
Why it matters
The acquisition of Crinetics Pharmaceuticals, which added PALSONIFY for acromegaly as a fourth commercial pillar, contributed $10 million in revenue following its close. The strong quarterly performance and revised outlook indicate continued expansion of Vertex Pharmaceuticals' product portfolio.
From dailypolitical.com
Who's involved
- Vertex PharmaceuticalsAmerican pharmaceutical company reporting Q3 results and raising guidance
- Crinetics PharmaceuticalsCompany acquired by Vertex Pharmaceuticals in September, contributing revenue
- Reshma KewalramaniCEO and President of Vertex Pharmaceuticals
- Duncan McKechnieExecutive, EVP, at Vertex Pharmaceuticals
Keep exploring
The entities involved
-
Vertex Pharmaceuticals
American pharmaceutical company